Features

LAGOS (Capital Markets in Africa) — Donald Trump’s lawyers begin their defense of the former president in his Senate impeachment trial on Friday after House Democrats spent two days portraying him as a lawless, unrepentant inciter of the Jan. 6 insurrection at the U.S. Capitol who shouldn’t hold public office again. Lawyers for the former president are expected to argue that he didn’t provoke the violence and will show video footage of prominent Democrats using…

LAGOS (Capital Markets in Africa) — Adapted from “How to Avoid a Climate Disaster: The Solutions We Have and the Breakthroughs We Need,” publishing on February 16 from Alfred A. Knopf. We need to get to zero emissions, and we’re going to need a lot of innovation to do it. But innovation doesn’t happen overnight, and it will take decades for green products to reach a big enough scale to make a significant difference. In the…

LAGOS (Capital Markets in Africa) — Joe Biden began his presidency much as his predecessor did, promising to restore hope to a blue-collar middle class battered by decades of relentless job losses from automation and foreign competition. But the realities of trying to stoke U.S. manufacturing employment in the wake of an economic crisis are quickly endangering his plans. After a period of recovery last year, U.S. factory payrolls stagnated in recent months, then went into reverse…

LAGOS (Capital Markets in Africa) — Viruses mutate all the time, including the novel coronavirus that’s caused the global Covid-19 pandemic. Most of the changes have no apparent effect. But recent variants that have emerged in the U.K., South Africa, and Brazil are causing particular concern. Studies suggest they are more contagious, and some evidence points to the U.K. strain being more deadly. An increase in infections has led to a surge in hospitalizations and…

JOHANNESBURG (Capital Markets in Africa) — The lead researcher of the South African trial of AstraZeneca Plc’s coronavirus vaccine urged authorities in the country to continue using the shot to cut death and hospitalization rates and the chance of further virus mutations. Early data of a small phase trial published Sunday showed that AstraZeneca’s vaccine has limited efficacy against mild disease caused by the B.1.351 variant that’s now dominant in South Africa, prompting the government…